William Barry, MD
Interventional Cardiology · Colorado Springs, CONPI 1598752644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,662 of the $5,697 with a category attached, or 81.8%. 23 manufacturers reported payments, led by Boston Scientific at 34.9% of the total. Reporting peaked in 2020 at $1,867 and has fallen 62.0% since, to $709 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CO, where the typical reported total is $6,820.
Across 179 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Edwards Lifesciences$1K
- E.r. Squibb & Sons, L.L.C.$376
- Amgen$346
- Pfizer$272
- Medtronic$238
- plus $1K from 17 others
Across 38 payments — averaging $4374.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$136K
- Novartis$30K
What the payments were for
- Travel & lodging$1,03418%
- Food & beverage$4,66282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 57 | $1,986 |
| Edwards Lifesciences | 9 | $1,478 |
| E.r. Squibb & Sons, L.L.C. | 20 | $376 |
| Amgen | 19 | $346 |
| Pfizer | 15 | $272 |
| Medtronic(2 entities) | 10 | $238 |
| Novartis | 12 | $222 |
| Abbott | 3 | $136 |
| Chiesi USA, Inc. | 6 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Alnylam Pharmaceuticals Inc. | 3 | $67 |
| Boehringer Ingelheim | 4 | $57 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Bridgebio Pharma, Inc. | 2 | $53 |
| Johnson & Johnson | 3 | $38 |
| Asahi Intecc USA, Inc. | 1 | $31 |
| Abiomed | 1 | $25 |
| Heartflow, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,697 in reported general payments places this provider in the 45th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $310,951 |
| EliquisApixaban | 178 | $249,490 |
| Repatha SureclickEvolocumab | 93 | $114,302 |
| EntrestoSacubitril/Valsartan | 49 | $66,092 |
| XareltoRivaroxaban | 42 | $55,531 |
| Praluent PenAlirocumab | 46 | $39,383 |
| JardianceEmpagliflozin | 24 | $24,280 |
| Ezetimibe | 223 | $9,393 |
| Rosuvastatin Calcium | 599 | $8,733 |
| BrilintaTicagrelor | 11 | $8,457 |
| Metoprolol Succinate | 424 | $5,774 |
| Telmisartan | 103 | $3,609 |
| Amlodipine Besylate | 279 | $2,108 |
| Atorvastatin Calcium | 255 | $1,972 |
| Losartan Potassium | 228 | $1,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $272 | $560,441190 claims |
| NovartisEntresto | $222 | $66,09249 claims |
| Johnson & JohnsonXarelto | $38 | $55,53142 claims |
| Boehringer IngelheimJardiance | $57 | $24,28024 claims |
| AstraZenecaBrilinta | $15 | $8,45711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Colorado Springs
- Cihan CevikColorado Springs$64K
- Joseph LeeColorado Springs$15K
- Bishal BhandariColorado Springs$12K
- Harshal PatilColorado Springs$9K
- Christopher KovachColorado Springs$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.